Comple.med Launches the First Food Supplement in Europe Featuring IMMUSE®
Kyowa Hakko's IMMUSE®, a clinically researched unique postbiotic, provides immune support in Lactoflor® Immuno 200
MILAN, Italy, Feb. 1, 2023 /PRNewswire-PRWeb/ -- Comple.med, an Italian based company engaged in the field of Complementary Medicines with an emphasis on phytotherapy, recently added a new product to their lineup of food supplements and phytotherapeutics. Lactoflor® Immuno 200 is the first product to launch in Europe featuring IMMUSE®. The formulation contains 50mg of IMMUSE®, 200 mg of Lactoferin and 25 mcg of Vitamin D3.
IMMUSE® Lactococcus lactis strain Plasma (LC-plasma), is a unique and patented postbiotic that proactively supports the immune system through a novel method of action that activates pDC (plasmacytoid dendritic cells). The pDC, a rare type of immune cell, has been shown to activate pivotal cells such as NK, Killer-T, Helper-T, and B cells, for a more comprehensive approach to immune support. It is this mechanism of action that differentiates IMMUSE® from more conventional lactic acid bacteria or other immune ingredients.
"Immune health is a growing market sector in Europe, and we are so pleased to see our IMMUSE® ingredient formulated into a Comple.med product, understanding the exacting standards they employed before bringing this innovative formulation to market," commented Oksana Ritchie, Head of Marketing at Kyowa Hakko Europe.
Before incorporating IMMUSE® into Lactoflor® Immuno 200 , Comple.med undertook a rigorous process to ensure the highest standards and quality profiles consistent with the company's pursuit of excellence. According to Eugenio Borghi, Comple.med director and research and development manager :"We consider Kyowa Hakko to be a trusted partner who support all their ingredients with comprehensive and in-depth science. That is very important to our company as we work to educate professionals in the health sector on the most appropriate and scientifically correct use of food supplements and phytotherapeutics."
IMMUSE® is backed by 29 published studies, including 14 human clinical trials, and over 10 years of research. It is marketed and sold by Kyowa Hakko, an international ingredients manufacturer whose primary goal is to provide health solutions that support optimal health for improved quality of life.
For more information about IMMUSE®, visit https://immusehealth.com/.
For media inquiries, please contact Oksana Ritchie at firstname.lastname@example.org.
About Kyowa Hakko Europe and Kyowa Hakko Bio Italia
Kyowa Hakko Europe and Kyowa Hakko Bio Italia are the Central-North and South European sales office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. For more information, visit http://www.kyowa.eu.
IMMUSE® is a postbiotic that delivers a new, breakthrough approach to broad range immune support*. As a clinically researched immune activator* supported by 29 published studies, including 14 human trials, IMMUSE® proactively supports the immune system through a novel method of action that activates pDC (plasmacytoid dendritic cells)*. The pDC, a rare type of immune cell, functions as the key leader of the immune system and has been shown to activate pivotal cells such as NK, Killer-T, Helper-T, and B cells, for a more comprehensive approach to immune support*. Its unique mechanism of action, discovered by Kyowa Hakko's parent company Kirin Holdings Co., Ltd., is opening doors for discovering postbiotics concerning immune health.
Comple.med is a company engaged in the field of Complementary Medicines with an emphasis on phytotherapy, the scientific and rational use of Medicinal Plants (evidence-based medicine). Comple.med designs and markets food supplements, phytotherapeutics, and cosmeceuticals suitable for the main needs of physiological rebalancing, health and well-being that increasingly large sectors of the population require. Directed by a scientific and technical staff composed of biologists and pharmacists, Compl.med works to educate professionals in the health sector on the most appropriate and scientifically correct use of food supplements and phytotherapeutics. For more information, visit https://www.complemed.biz/
Oksana Ritchie, Kyowa Hakko, +49 211 175 450, email@example.com
SOURCE Kyowa Hakko
Upcoming Life Sciences Events
- June 2023
- Boston: Product & Company Valuation Course
- BIO International Convention 2023
- RESI Boston
Latest company news
Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis
Mediso installs 100% cryogen-free 7T MRI at the University of Milano-Bicocca, Italy
Merck Study: mRNA Technology a 'Game Changer' for Asia-Pacific Vaccine Manufacturers